On March 26, 2025, Candel Therapeutics announced positive final survival data from its phase 2a trial of CAN-2409 for advanced non-small cell lung cancer, showing a median overall survival of 24.5 months for patients inadequately responding to prior treatment, with 37% surviving over 24 months.